Bicyclic peptide-enhanced covalent inhibitor of SARS-CoV-2 3CL protease
Aim: Develop technology to apply bicyclic peptides for discovering covalent inhibitors of proteases and use this technology to create bicyclic peptide—warhead conjugates for targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3C-like (3CL) protease. Enhance the potency of the...
Saved in:
| Main Authors: | Qian Wang, Yanhui Wang, Jian Li, Hong Liu, Shiyu Chen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration
2024-10-01
|
| Series: | Exploration of Drug Science |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/uploads/Article/A100871/100871.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Orthogonal dual reporter-based gain-of-signal assay for probing SARS-CoV-2 3CL protease activity in living cells: inhibitor identification and mutation investigation
by: Zhu-Chun Bei, et al.
Published: (2023-12-01) -
<i>In Silico</i> Development of SARS-CoV-2 Non-Covalent Mpro Inhibitors: A Review
by: Islam Alagawani, et al.
Published: (2025-06-01) -
Efficacy and safety of 3CL protease inhibitors in patients with mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials
by: Nicole Jean Lee, et al.
Published: (2025-08-01) -
Novel peptide inhibitor for the Chikungunya virus nsP2 protease: Identification and characterization
by: Mohammadamin Mastalipour, et al.
Published: (2025-01-01) -
α-Heteroarylthiomethyl ketones: Small molecule inhibitors of 3CLpro
by: Knez Damijan, et al.
Published: (2025-06-01)